LY4086940
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Eli Lilly · Phase 1 · Completed · Enrollment 219
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Part A: LY4086940 Single Dose (Healthy Participants) | n/r | n/r | n/r | n/r |
| Part A: Placebo Single Dose (Healthy Participants) | n/r | n/r | n/r | n/r |
| Part A: LY4086940 Multiple Dose (Healthy Participants) | n/r | n/r | n/r | n/r |
| Part A: Placebo Multiple Dose (Healthy Participants) | n/r | n/r | n/r | n/r |
| Part B: LY4086940 Multiple Dose (Participants with Overweight or Obesity) | n/r | n/r | n/r | n/r |
| Part B: Placebo Multiple Dose (Participants with Overweight or Obesity) | n/r | n/r | n/r | n/r |
| Part C: LY4086940 Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity) | n/r | n/r | n/r | n/r |
| Part C: Placebo Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity | n/r | n/r | n/r | n/r |
| Part D: LY4086940 Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity) | n/r | n/r | n/r | n/r |
| Part D: Placebo Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity) | n/r | n/r | n/r | n/r |
| Part E (Open-Label): LY4086940 Single Dose (Healthy Participants) | n/r | n/r | n/r | n/r |
Not shown
- Part A: LY4086940 Single Dose (Healthy Participants): endpoint not reported
- Part A: Placebo Single Dose (Healthy Participants): endpoint not reported
- Part A: LY4086940 Multiple Dose (Healthy Participants): endpoint not reported
- Part A: Placebo Multiple Dose (Healthy Participants): endpoint not reported
- Part B: LY4086940 Multiple Dose (Participants with Overweight or Obesity): endpoint not reported
- Part B: Placebo Multiple Dose (Participants with Overweight or Obesity): endpoint not reported
- Part C: LY4086940 Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity): endpoint not reported
- Part C: Placebo Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity: endpoint not reported
- Part D: LY4086940 Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity): endpoint not reported
- Part D: Placebo Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity): endpoint not reported
- Part E (Open-Label): LY4086940 Single Dose (Healthy Participants): endpoint not reported